STCube Presents Research Results on Immune Checkpoint Inhibitor ‘hSTC810’ at American Association for Cancer Research Conference

[Asia Economy Reporter Jang Hyowon] STCube, a bio company developing immune checkpoint inhibitors, announced on the 15th that it presented additional research results on its innovative drug candidate ‘BTN1A1’ at the Society for Immunotherapy of Cancer (SITC) conference in the United States.

SITC is one of the most prestigious immuno-oncology societies worldwide, with over 4,650 scientists, researchers, and clinicians from 63 countries sharing the common goal of cancer patient treatment. The annual conference is held every November. This year’s 36th conference was held from the 10th to the 14th in Washington, USA, both online and in-person.

At SITC, STCube revealed that the newly discovered immune checkpoint protein ‘BTN1A1’ acts as an upstream regulator of PD-L1, which is used as a biomarker for existing immune checkpoint inhibitors.

According to STCube’s research, the ‘BTN1A1’ protein target showed a high expression rate in solid tumors, which are refractory diseases with low PD-L1 expression, and was expressed mutually exclusively without overlapping with PD-L1, demonstrating a synergistic effect with PD-L1. STCube expects ‘BTN1A1’ to be a useful therapeutic agent for patients who are non-responsive to existing immune checkpoint inhibitor treatments as an upstream regulator of PD-L1.

Additionally, through CDX experiments using humanized mice with the lung cancer cell line (A549), STCube identified that the ‘hSTC810’ antibody targeting ‘BTN1A1’ effectively inhibits tumor growth and is predominantly expressed in tumor cells compared to existing ‘PD-L1’.

A company representative stated, “After presenting the SITC abstract, multinational pharmaceutical companies showed great interest in the preclinical results and global clinical entry of the innovative drug candidate ‘hSTC810,’ and further meetings are planned.” He added, “We plan to continuously share the research results of ‘BTN1A1’ through conference participation and paper publications.”

He continued, “Ahead of submitting the global clinical trial plan (IND) to the U.S. Food and Drug Administration (FDA) scheduled for this year, we completed a Pre-IND meeting with the FDA in September and are accelerating preparations for global clinical entry early next year.”

This content was produced with the assistance of AI translation services.